Press Releases September 9, 2026 07:00 AM

MapLight Therapeutics to Participate in Upcoming Investor Conference

MapLight Therapeutics to Present at Morgan Stanley Annual Global Healthcare Conference

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
MPLT

MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, announced its management team's participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The company aims to highlight its innovative discovery platform targeting neural circuits linked to diseases, with presentations and one-on-one meetings scheduled for the event.

MapLight Therapeutics to Participate in Upcoming Investor Conference
MPLT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MapLight Therapeutics will present and hold 1x1 meetings at a major healthcare investor conference, increasing visibility among investors.
  • The company focuses on developing circuit-specific pharmacotherapies for central nervous system disorders using a novel discovery platform.
  • Participation at this event could enhance investor awareness and potential partnerships in the biotechnology and pharmaceutical sectors.

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:

Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)
Date: Monday, September 14th
Format: Presenting and hosting 1x1 meetings

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.

For investor inquiries: [email protected]

For media inquiries: [email protected]


Risks

  • As a clinical-stage biopharmaceutical company, MapLight faces inherent risks related to clinical trial outcomes and regulatory approvals impacting drug development.
  • The success of their novel discovery platform in identifying effective therapies is uncertain and could affect future growth.
  • The biotechnology sector is subject to market volatility based on scientific, regulatory, and competitive developments, which could influence investor sentiment.

More from Press Releases

Raytech Holding Limited Announces Official Name Change to “Atlas Trinity Tech Limited” and New Ticker Symbol “ATTT” Effective September 10, 2026 Sep 9, 2026 Smithfield® Expands Commonwealth Clash Presenting Sponsorship with New Fan and Community Initiatives Sep 9, 2026 AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video Sep 9, 2026 Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada’s GLP-1 Program Sep 9, 2026 T3 Defense to Present at the H.C. Wainwright Global Investment Conference on September 14-16 Sep 9, 2026